March 5, 2023

Ionis Pharmaceuticals plans large expansion in Carlsbad

San Diego Union Tribune

Ionis Pharmaceuticals, which recently announced it will open a sprawling research-and-development center in Oceanside, also plans a large expansion of its home base in Carlsbad....
READ MORE »

February 16, 2023

The potential next pathway to target in CVD prevention: ‘Common’ elevated Lp(a)

Healio

About 20% of the global population and one in five U.S. adults have elevated levels of lipoprotein(a), a complex form of LDL that strongly predicts risk for coronary disease and aortic valve stenosis. Evidence for a causal association between Lp(a) concentration, which is primarily genetically determined, and CV outcomes across ethnicities continues to build....
READ MORE »

January 10, 2023

Roche, Ionis launch new Huntington’s disease study

Endpoints News


READ MORE »

November 22, 2022

After blazing trails in RNA-targeted drugs, Ionis jumps into gene editing

Stat

Ionis Pharmaceuticals, the California company that turned RNA-targeting medicines from an unproven idea into blockbuster drugs, is now expanding into a new class of therapeutics that treat disease by editing DNA. ...
READ MORE »

November 14, 2022

Ionis teams with Metagenomi and dives into gene editing

Biopharma Dive

Ionis Pharmaceuticals has formed an alliance with gene editing startup Metagenomi in a bid to branch out beyond the RNA-based drugs it’s known for....
READ MORE »

October 13, 2022

Ionis to build new manufacturing site in Southern California, doubling the size of its current site

Endpoints News

As Ionis continues to net major deals and collaborations with large pharma companies, the California-based biotech is looking to expand its manufacturing capacity. Ionis will have a chemistry and manufacturing site built in the city of Oceanside, CA, north of San Diego....
READ MORE »